PharmaTher advances in work to develop microneedle patch for psychedelics

Toronto company seeks to come up with alternative way to administer psychedelic substances.

Transdermal patches are discreet and convenient to use. Jun/Getty Images


PharmaTher Holdings Ltd. has made a new advance in developing an alternative way to deliver psychedelics.

The Toronto company announced Tuesday (December 14) positive results in its study about the feasibility of a proprietary microneedle patch for LSD.

Known on the street as acid, LSD stands for lysergic acid diethylamide.

The potent psychedelic drug is made from lysergic acid found in a fungus that grows on rye and other grains.

Microneedle patches are seen as a discreet and painless way of administering various substances, including vaccines, through the skin.

PharmaTher operates as a biotech company, whose focus includes delivery methods for psychedelics to treat mental and physical disorders.

In its December 14, 2021 media release, the company stated that its patch could “enable flexible drug load capacity and combinations, controlled released delivery, and be able to present desired pharmacokinetic and safety profiles”.

“In addition, the MicroDose-MN™ patch for psychedelics aims to empower patients to dose their medication remotely, safely and conveniently rather than under supervision by a healthcare provider at a certified medical office or hospital,” PharmaTher stated.

It added that “anti-tampering and anti-abuse features” will be incorporated in the system.

On November 11 this year, the company announced that it achieved encouraging results from its study on the transdermal administration of psilocybin, another psychedelic substance.

PharmaTher hopes that microneedle patches will also work for other psychoactive substances like ketamine; 3,4-methylenedioxy-methamphetamine or MDMA, commonly known as ecstasy; and N, N-dimethyltryptamine or DMT, the hallucinogenic element found in ayahuasca, a psychedelic brew.

On June 1, 2021, PharmaTher and TSRL, Inc. announced that they are partnering to develop microneedle patches.

The announcement related that the venture seeks to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University Belfast.

TSRL is a Michigan company interested in incorporating antiviral medications in a microneedle patch.

“Microneedle-enhanced intradermal delivery is an elegant, efficient and painless method for increasing the skin permeation of many drugs, including psychedelics, antiviral therapeutics and vaccines,” the June 1 media release explained.

Moreover, the system “addresses a major unmet need by offering greater ease of administration, inclusion of patients with pre-existing conditions that exempt them from oral or inhalation dosing”.

“It avoids syringe needles, eliminating pain and patient visits to a clinician,” the release noted.

PharmaTher trades in the Canadian Securities Exchange under the ticker symbol PHRM.

Follow Carlito Pablo on Twitter at @carlitopablo

Leave your opinion for the editor...We read everything!

Your email address will not be published. Required fields are marked *